Phase I study of dasatinib in combination with capecitabine, oxaliplatin and bevacizumab followed by an expanded cohort in previously untreated metastatic colorectal cancer

By Strickler John   McCall Shannon   Nixon Andrew   Brady John   Pang Herbert   Rushing Christel   Cohn Allen   Starodub Alexander   Arrowood Christy   Haley Sherri   Meadows Kellen   Morse Michael   Uronis Hope   Blobe Gerard   Hsu S.   Zafar S.   Hurwitz Herbert  

Investigational New Drugs, Vol. 32, Iss. 2, 2014-04 ,pp. : 330-339

Springer Publishing Company

Access to resources Recommend Favorite

Capecitabine: A Review of its Use in the Treatment of Advanced or Metastatic Colorectal Cancer

By McGavin J.K.   Goa K.L.  

Drugs, Vol. 61, Iss. 15, 2001-01 ,pp. : 2309-2326

Adis International

Access to resources Recommend Favorite

A phase II study of S-1 plus irinotecan and oxaliplatin in heavily-treated patients with metastatic colorectal cancer

By Kim Sun   Hong Yong   Kim Byung   Park Ji   Choi Hyo   Jeong Seung-Yong   Kim Dae   Hong Chang   Sohn Dae   Jung Kyung  

Investigational New Drugs, Vol. 27, Iss. 3, 2009-06 ,pp. : 269-274

Springer Publishing Company

Access to resources Recommend Favorite

FOLFOXIRI promising in metastatic colorectal cancer

By  

Inpharma, Vol. 1, Iss. 1587, 2007-01 ,pp. : 18-18

Adis International

Access to resources Recommend Favorite

Capecitabine plus paclitaxel in metastatic breast cancer

By  

Inpharma, Vol. 1, Iss. 1444, 2004-01 ,pp. : 11-11

Adis International

Access to resources Recommend Favorite